Federal Register of Legislation - Australian Government

Primary content

PB 73 of 2019 Determinations/Health as made
This determination amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015) to determine an originator brand of a new pharmaceutical item for the PBS F2 formulary.
Administered by: Health
Registered 30 Aug 2019
Tabling HistoryDate
Tabled HR09-Sep-2019
Tabled Senate09-Sep-2019
To be repealed 15 Nov 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 73 of 2019

National Health (Originator Brand) Amendment Determination 2019 (No. 6)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated         29 August 2019

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health



1              Name of Determination

                 (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2019 (No. 6).

(2)     This Determination may also be cited as PB 73 of 2019.

2              Commencement

                This Determination commences on 1 September 2019.

3              Amendments to PB 100 of 2015

                Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).


Schedule 1     Amendments

(section 3)

[1]                   Schedule 1, (table item 28B)

Repeal the item:

28B

Buprenorphine

Subutex

Sublingual

 

 

 

Norspan

Transdermal

 

Substitute:

28B

Buprenorphine

Buvidal Monthly

Buvidal Weekly

Injection

 

 

 

Subutex

Sublingual

 

 

 

Norspan

Transdermal